Compare IPWR & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPWR | PLRX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | 17 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.4M | 68.7M |
| IPO Year | 2013 | 2020 |
| Metric | IPWR | PLRX |
|---|---|---|
| Price | $3.98 | $1.09 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 4 |
| Target Price | ★ $10.75 | $2.67 |
| AVG Volume (30 Days) | 184.8K | ★ 706.8K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2,603.56 | N/A |
| Revenue Next Year | $1,800.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.62 | $1.05 |
| 52 Week High | $9.30 | $1.95 |
| Indicator | IPWR | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 33.12 | 40.45 |
| Support Level | $2.80 | N/A |
| Resistance Level | $4.44 | $1.37 |
| Average True Range (ATR) | 0.32 | 0.05 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 8.89 | 19.23 |
Ideal Power Inc is engaged in the development of its broadly patented bidirectional power switches, creating efficient and ecofriendly energy control solutions for electric vehicles, electric vehicle charging, renewable energy, energy storage, UPS / data center, solid-state circuit breaker and other industrial and military applications. The company is focused on its patented Bidirectional, Bipolar Junction Transistor (B-TRAN) semiconductor technology. B-TRAN is a double-sided bidirectional AC switchable to deliver substantial performance improvements over conventional power semiconductors. The primary raw material used in the fabrication of B-TRAN devices is silicon wafers.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.